282 related articles for article (PubMed ID: 30358109)
1. Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis.
Guo X; Wang S; Godwood A; Close D; Ryan PC; Roskos LK; White WI
Int J Rheum Dis; 2019 Apr; 22(4):646-653. PubMed ID: 30358109
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
Weinblatt ME; McInnes IB; Kremer JM; Miranda P; Vencovsky J; Guo X; White WI; Ryan PC; Godwood A; Albulescu M; Close D; Burmester GR
Arthritis Rheumatol; 2018 Jan; 70(1):49-59. PubMed ID: 28941039
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
[TBL] [Abstract][Full Text] [Related]
4. Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
Guo X; Higgs BW; Bay-Jensen AC; Wu Y; Karsdal MA; Kuziora M; Godwood A; Close D; Ryan PC; Roskos LK; White WI
Rheumatology (Oxford); 2018 Jan; 57(1):175-184. PubMed ID: 29069507
[TBL] [Abstract][Full Text] [Related]
5. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
Burmester GR; McInnes IB; Kremer J; Miranda P; Korkosz M; Vencovsky J; Rubbert-Roth A; Mysler E; Sleeman MA; Godwood A; Sinibaldi D; Guo X; White WI; Wang B; Wu CY; Ryan PC; Close D; Weinblatt ME;
Ann Rheum Dis; 2017 Jun; 76(6):1020-1030. PubMed ID: 28213566
[TBL] [Abstract][Full Text] [Related]
6. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.
Burmester GR; Feist E; Sleeman MA; Wang B; White B; Magrini F
Ann Rheum Dis; 2011 Sep; 70(9):1542-9. PubMed ID: 21613310
[TBL] [Abstract][Full Text] [Related]
7. Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.
Burmester GR; McInnes IB; Kremer JM; Miranda P; Vencovský J; Godwood A; Albulescu M; Michaels MA; Guo X; Close D; Weinblatt M
Arthritis Rheumatol; 2018 May; 70(5):679-689. PubMed ID: 29361199
[TBL] [Abstract][Full Text] [Related]
8. Targeting GM-CSF in rheumatoid arthritis.
Avci AB; Feist E; Burmester GR
Clin Exp Rheumatol; 2016; 34(4 Suppl 98):39-44. PubMed ID: 27586802
[TBL] [Abstract][Full Text] [Related]
9. Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF
Bystrom J; Clanchy FI; Taher TE; Al-Bogami MM; Muhammad HA; Alzabin S; Mangat P; Jawad AS; Williams RO; Mageed RA
Clin Rev Allergy Immunol; 2017 Oct; 53(2):265-276. PubMed ID: 28488248
[TBL] [Abstract][Full Text] [Related]
10. Honokiol possesses potential anti-inflammatory effects on rheumatoid arthritis and GM-CSF can be a target for its treatment.
Wang XD; Wang YL; Gao WF
Int J Clin Exp Pathol; 2015; 8(7):7929-36. PubMed ID: 26339358
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid arthritis: new monoclonal antibodies.
Serio I; Tovoli F
Drugs Today (Barc); 2018 Mar; 54(3):219-230. PubMed ID: 29771256
[TBL] [Abstract][Full Text] [Related]
12. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
Genovese MC; Greenwald M; Cho CS; Berman A; Jin L; Cameron GS; Benichou O; Xie L; Braun D; Berclaz PY; Banerjee S
Arthritis Rheumatol; 2014 Jul; 66(7):1693-704. PubMed ID: 24623718
[TBL] [Abstract][Full Text] [Related]
13. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
14. Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients.
Ciechomska M; Bonek K; Merdas M; Zarecki P; Swierkot J; Gluszko P; Bogunia-Kubik K; Maslinski W
Arch Immunol Ther Exp (Warsz); 2018 Oct; 66(5):389-397. PubMed ID: 29744553
[TBL] [Abstract][Full Text] [Related]
15. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date.
Crotti C; Raimondo MG; Becciolini A; Biggioggero M; Favalli EG
Drug Des Devel Ther; 2017; 11():211-223. PubMed ID: 28144129
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
[TBL] [Abstract][Full Text] [Related]
19. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study.
Takeuchi T; Tanaka Y; Close D; Godwood A; Wu CY; Saurigny D
Mod Rheumatol; 2015 Jan; 25(1):21-30. PubMed ID: 24720551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
